Neumora Therapeutics is trading 5.59% up at $1.60 despite broader market weakness on August 18, 2026, with no new company-specific announcement clearly explaining the intraday gain.
- The latest material update was the August 14 earnings release.
- It highlighted a cash runway into the third quarter of 2027, an obesity-program pivot, and Joshua Pinto’s appointment as CEO.
- Those developments appear to be background context rather than a confirmed catalyst for the August 18 move.